Abstract Submission (General)
Abstract SubmissionAbstract Submission Guidelines
- Language: English.
- Title, Affiliation, Name, Abstract (Please prepare your data in this order)
- The title of abstract must be within 200 characters.
- The body of abstract should NOT exceed 1,100 characters.
- Tables and images are NOT allowed.
- Abstract Structure: Purpose-Methods-Results-Conclusions
After submitting the abstract, you will receive an E-mail confirming the receipt of your abstract.
If you do not receive this e-mail, please contact the congress secretariat.
(jspaci59@sunpla-mcv.com)
Abstract Submission Categories, Topic Categories
Please choose your abstract submission category "Oral in person", "Digital poster" or "Either is fine".
Topic Categories are below.
| 01 | Epidemiology of Allergic Diseases | 02 | Prevention of Allergic Diseases |
|---|---|---|---|
| 03 | Mechanisms of Allergic Diseases | 04 | Treatment of Allergic Diseases |
| 05 | Atopic Dermatitis: Epidemiology | 06 | Atopic Dermatitis: Pathology |
| 07 | Atopic Dermatitis: Diagnosis, Test | 08 | Atopic Dermatitis: Treatment |
| 09 | Atopic Dermatitis: Prognosis, QOL | 10 | Asthma: Epidemiology |
| 11 | Asthma: Pathology | 12 | Asthma: Diagnosis, Test |
| 13 | Asthma: Treatment | 14 | Asthma: Prognosis, QOL |
| 15 | Immediate-type Food Allergy: Epidemiology | 16 | Immediate-type Food Allergy: Pathology |
| 17 | Immediate-type Food Allergy: Diagnosis | 18 | Immediate-type Food Allergy: Test |
| 19 | Immediate-type Food Allergy: Oral Food Challenge | 20 | Immediate-type Food Allergy: Treatment (Immunotherapy) |
| 21 | Immediate -type Food Allergy: Prognosis, QOL | 22 | Pollen-Food Allergy Syndrome (PFAS) |
| 23 | Food-Dependent Exercise-Induced Anaphylaxis | 24 | Food protein-induced enterocolitis (FPIES) |
| 25 | Food protein-induced enteropathy (FPE) | 26 | Food protein-induced proctocolitis (FPIAP) |
| 27 | Eosinophilic Gastro-Intestinal Disorder（EGID） | 28 | Ocular Allergy, Nasal Allergy, Pollen Allergy |
| 29 | Drug Allergy | 30 | Anaphylaxis |
| 31 | Immunodeficiency Disease | 32 | Immunizatioin |
| 33 | Healthcare team | 34 | Education, Guidance |
| 35 | Others |
Acceptance Notification
All submitted abstracts will be reviewed by the scientific committee according to review procedures. Notification of acceptance will be informed by E-mail to presenter/corresponding author.
Abstract withdrawal
Abstract modification is possible until submission deadline. If you have to withdraw the abstract after the deadline, please inform the secretariat by E-mail by July 31 (Sun), 2022.
Publication of abstracts
Accepted abstracts will be published in the Nihon Shoni Arerugi Gakkaishi (The Japanese Journal of Pediatric Allergy and Clinical Immunology).
Ethical Guidelines
- The abstract must be based on scientific evidence and be consistent with the content of the abstract.
- The abstract presentation is not intended for commercial use.
- COI status must be disclosed in accordance with the "Common Guidelines on Conflict of Interest (COI) in Medical Research" and its detailed regulations.
- The authors are responsible for giving sufficient consideration to the protection of privacy.
- The study reported in the abstract involved human subjects and it meets the ethical principles of the Declaration of Helsinki.
- With the exception of case reports of less than five cases, the abstract of human research must be been approved by the Ethics Review Committee or IRB (Investigational Review Board) of each institution.
- The abstract involved animal experiments must meet the relevant guidelines for the care and use of laboratory animals.
Please note that if there is any doubt about the content of your presentation after the fact, you may be asked to submit an approval document.
COI (Conflict of Interest Disclosure)
All authors are required to disclose any financial relationship within the past 3 years with a biotechnology manufacturer, a pharmaceutical company, or other commercial entities that have an interest in the subject matter or materials discussed in the abstract and presentation. The matters requiring disclosure are outlined in the JSPACI Conflict of Interest Policy.
The details of COI declaration in the presentation slides will be informed on the congress website.
Personal Financial Interests
- Employment/Leadership position/Advisory role
(1,000,000 yen or more from one commercial entity) - Stock ownership or options
(Profit of 1,000,000 yen or more from one commercial entity / ownership of 5% or more of total shares of one company) - Patent royalties/licensing fees
(1,000,000 yen or more per one royalty/licensing fee) - Honoraria (e.g. lecture fees)
(500,000yen or more annually from one commercial entity) - Fees for promotional materials (e.g. Manuscript fees)
(500,000yen or more from one commercial entity) - Research funding
(5,000,000 yen or more from one commercial entity) - Scholarship donation
(1,000,000 yen or more from one commercial entity) - Endowed departments by commercial entities
(If any of the authors belongs to an endowed department sponsored by any commercial entity) - Others (e.g. trips, travel, or gifts, that are not related to research)
(50,000 yen or more from one commercial entity)
*Please refer to the current currency exchange rate for Japanese Yen at an appropriate website.
Abstract SubmissionReference / Update
Congress Secretariat
Sunplanet Co., Ltd.
E-mail: jspaci59@sunpla-mcv.com
*As we work remotely, please contact us by E-mail.